EB-002
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken orally. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. Its exact chemical structure does not yet appear to have been disclosed.
EB-002, also formerly known as EB-373, is a synthetic prodrug of the non-selective serotonin receptor agonist and serotonergic psychedelic psilocin which is under development for the treatment of neuropsychiatric disorders like depression and anxiety disorders. It is taken orally. The drug is under development by Enveric Biosciences. As of November 2024, it is in the preclinical research stage of development. In November 2024, Enveric Biosciences out-licensed EB-002 to MycoMedica Life Sciences in a deal that was estimated to be worth as much as $62 million. Its exact chemical structure does not yet appear to have been disclosed.
See also
Substituted tryptamine List of investigational hallucinogens and entactogens CT-4201, MSP-1014, and RE-109 (4-GO-DMT) Luvesilocin (4-GO-DiPT)
References
External links
EB-373 - Pipeline - Enveric Biosciences
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372018743 under CC BY-SA 4.0; modifications have been made.